MedTrace Logo

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

NCT06968572 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2025-05-13

No results posted yet for this study

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.

Conditions

Interventions

DRUG

HSK41959

Oral administration, QD

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2026-03-26
Completion
2028-05-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06968572 on ClinicalTrials.gov